Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Riemser Arzneimittel acquires Curasan dental product line
Curasan, based in Research Triangle Park, North Carolina, which had been marketing the family of bone regeneration and membrane products in the US since 2004, will now be
Curasan, based in Research Triangle Park, North Carolina, which had been marketing the family of bone regeneration and membrane products in the US since 2004, will now be
Under the letter of intent (LOI), Trimedyne has offered to license seven of its US patents and two US patent applications exclusively to FemSuite for any use in
Celsion and Yakult have executed a letter of intent relating to the commercialization of ThermoDox for the Japanese markets, which is subject to the execution of definitive agreements.
The company expects to launch the product at the end of the fourth quarter of 2008. Zhiqiang Han, president and COO of BMP Sunstone, said: “We are excited
After the acquisition, SIS will remain in Herzogenrath, near Aachen, Germany and will be renamed to ‘Bruker Nano’. Frank Saurenbach and Hans-Achim Fuss will continue to lead the
Following the launch of its PanExcea performance excipient, Mallinckrodt Baker is teaming with Rubicon Research to expand its performance excipient platform. The two companies will develop and launch
The study, which was conducted in normal adult volunteers, showed that LT-NS001 was well-tolerated by the recipients. Moreover, when the subjects in the study were dosed twice daily
The study will be conducted at four clinical trial sites for a period of nine to 12 months and include up to 40 subjects. The drug will be
This study was a multi-centre, randomized, double blind, evaluation of the efficacy and safety of Uracyst versus placebo in patients with interstitial cystitis or painful bladder syndrome. The
The company also received a notice from the US Patent and Trademark Office that it intends to grant a patent with claims covering certain methods for treating multidrug-resistant